▲ Peaking
Business
Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Alameda-based Scribe Therapeutics has filed for a $75 million Nasdaq IPO, signaling a new test for investor interest in earlier-stage gene-editing firms.